This was the reaction from Dr Romain Nati, general director of CHL, following the open letter by the doctor's association that criticised him for his statements on the use of Remdesivir for Covid-19 patients.
AMMD accused Dr Nati of simultaneously fostering false hope and fears, since not all patients are treated with the Ebola drug, which is currently tested within the context of the French "Discovery" study at CHL.
The doctor's association underlined that the drug was still lacking research approval, although it had already been authorised for market sales.
Dr Nati explained that within his capacity as head of CHL, he would support all efforts of clinical research, since studies like "Discovery" would allow treating patients with promising and innovative molecules.
Naturally, Remdesivir cannot be considered a wonder drug, Dr Nati further admitted: "It would of course be best not to get infected in the first place. But with the help of studies, we can take a step closer to developing a vaccine."
